Tevogen Bio submitted IND for T cell treatment in COVID-19

, , , ,

On Oct. 14, 2020, Tevogen Bio announced that its Investigational New Drug (IND) application to develop a COVID-19 treatment using proprietary antigen specific T cell technology had been submitted to the US Food and Drug Administration (FDA). Tevogen partnered with Dr. Neal Flomenberg, chair of the Department of Medical Oncology at Thomas Jefferson University, with the intent to evaluate Tevogen’s T cell technology to treat hospitalized COVID-19 patients.

This collaboration aims to harness Tevogen’s proprietary immunotherapy platform and Dr. Flomenberg’s expertise in research and the transplantation of T cells so that both Tevogen and Dr. Flomenberg can conduct clinical trials of T cell treatments for COVID-19. Under normal circumstances, the body generates specific T cells to rid itself of viruses such as COVID-19. In the proposed trials, such T cells will be generated in the laboratory and administered to patients at the sicker end of the COVID-19 spectrum.

For four decades, Dr. Flomenberg has been at the forefront of immunogenetics and immunology. “We are extremely excited to reach this critical stage in advancing Tevogen’s T cell therapy for COVID-19 towards clinical trials,” Dr. Flomenberg said. “We expect our upcoming Phase I trial to generate data that will hopefully demonstrate the safety of these T cells, the optimal dose of cells we should administer, and how we should best combine them with current COVID-19 standards of care. Though first trials always focus on safety rather than effectiveness, we’re hopeful that we’ll also see evidence that these cells are effective against this virus.”

Yale-trained infectious disease epidemiologist Dr. Ryan Saadi is leading Tevogen’s efforts to develop a COVID-19 curative treatment. Dr. Saadi added, “Our mission is not only to develop a T cell therapy cure for COVID-19 and Influenza, but to do so affordably and at scale to meet the extraordinary demand this pandemic requires. I am also hopeful about the potential cancer solutions our oncology portfolio might contribute.”

In addition to developing its potential therapies, Tevogen is committed to organizational and manufacturing efficiency. This should allow it to engage in affordable innovation to the benefit of all patients.

Tags:


Source: Newswire
Credit:

LifeScienceHistory.com offers three advertising package options. Each package lnclude at least two digital images for multiple page placements and maximum exposure! Rates range from just $300 to $500 per month.